Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLD1 | Q13393 | 2/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.55 |
| ▸ | NCF1 | P14598 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | SORD | Q00796 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | BPTF | Q12830 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15863561 | 1.00 | PLD1 (0.59) | PLD1ADRB2NCF1HRH3SORD | |
| Hydrochloric Acid SCHEMBL31394440 | 0.98 | PLD1 (0.58) | PLD1ADRB2NCF1HRH3SORD | |
| Hydrochloric Acid SCHEMBL4808448 | 0.98 | PLD1 (0.58) | PLD1ADRB2NCF1HRH3SORD | |
| SCHEMBL9767811 | 0.86 | — | — | |
| SCHEMBL30775404 | 0.82 | SORD (0.56) | SORDALDH1A1DRD4TSHRSMN1; SMN2 | |
| SCHEMBL4453478 | 0.82 | SORD (0.56) | SORDALDH1A1DRD4TSHRSMN1; SMN2 | |
| SCHEMBL29611181 | 0.80 | SORD (0.54) | SORDALDH1A1HRH4CYP1A2DRD4 | |
| SCHEMBL209842 | 0.80 | SORD (0.54) | SORDALDH1A1HRH4CYP1A2DRD4 | |
| SCHEMBL209844 | 0.80 | SORD (0.54) | SORDALDH1A1HRH4CYP1A2DRD4 | |
| SCHEMBL6180963 | 0.79 | LSS (0.60) | SORDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110337293-A | Therapeutic compound | 新泽西鲁特格斯州立大学 | 2019-10-15 | — | — | CN | claimed |
| CN-106543089-A | A kind of synthetic method of Dasatinib intermediate | 山东铂源药业有限公司 | 2017-03-29 | — | — | CN | claimed |
| CN-102108092-B | 23-hydroxy betulinic acid derivative as well as preparation method and application thereof | UNIV JINAN | 2014-07-02 | — | — | CN | claimed |
| US-8202868-B2 | 4-piperazinyl-pyrimidine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2012-06-19 | — | — | US | claimed |
| CN-102108092-A | 23-hydroxy betulinic acid derivative as well as preparation method and application thereof | UNIV JINAN | 2011-06-29 | — | — | CN | claimed |
| EP-1778684-B1 | 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D<sb>3</sb> RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2009-12-16 | — | — | EP | claimed |
| US-20090264437-A1 | 4-Piperazinyl-Pyrimidine Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor | ABBOTT GMBH & CO. KG (DE) | 2009-10-22 | — | — | US | claimed |
| EP-1778684-A1 | 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D&lt;sb&gt;3&lt;/sb&gt; RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-05-02 | — | — | EP | claimed |
| WO-2006015842-A1 | 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-02-16 | — | — | WO | claimed |
| CN-1202087-C | Derivatives of acyl-piperazinil-pyrimidins, preparation thereof and application as medicaments | ESTEVE LABOR DR (ES) | 2005-05-18 | — | — | CN | claimed |
| CN-1268124-A | Acyl-piperazinyl-pyrimidine derivatives, their preparation and use as medicaments | ESTEVE LABOR DR (ES) | 2000-09-27 | — | — | CN | claimed |
| US-5059599-A | Anxiolytic agents | PIERRE FABRE MEDICAMENT (FR) | 1991-10-22 | — | — | US | claimed |
| WO-2026101698-A1 | HEPCIDIN MIMETIC COMPOUNDS AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20250382301-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | UNIV ARIZONA (US) | 2025-12-18 | — | — | US | disclosed |
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | Asteroid Therapeutics (US) | 2025-10-28 | — | — | US | disclosed |
| EP-3630779-B1 | ANTIBIOTIC RESISTANCE BREAKERS | KING S COLLEGE LONDON (GB) | 2025-09-03 | — | — | EP | disclosed |
| US-5563141-A | INHIBIT CELL ADHESION FOR EXAMPLE, PLATELET AGGRE GATION | ZENECA LIMITED (GB) | 1996-10-08 | — | — | US | disclosed |
| EP-0690847-A1 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994022835-A2 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1994-10-13 | — | — | WO | disclosed |
| US-5215967-A | AMINOACID DERIVATIVES INHIBITING RENIN | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | SREBF1, SREBF2, NR1H3 | PLD1 1658/4885ADRB2 2468/4885NCF1 2920/4885 |
| US-20090264437-A1 | 4-Piperazinyl-Pyrimidine Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor | ADRA1D, ADRA1A, ADRA2A | PLD1 516/4885ADRB2 32/4885NCF1 3179/4885 |
| US-20250382301-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK3, CLK1 | PLD1 1714/4885ADRB2 2777/4885NCF1 3847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.